
    
      This is a multi-centre, open-label, early access program (EAP) designed to provide treatment
      access to intravenous (IV) treatment regimen of 300 mg anifrolumab (MEDI-546) every 4 weeks
      (Q4W) for eligible patients with moderate-to-severe active SLE while receiving standard
      therapy. Anifrolumab will be provided free of charge to the patients entering this
      program.This global EAP will be opened in a sequential fashion, country by country, based on
      the requesting Treating Physician(s) and local regulations
    
  